Enliven CSO executes 10b5-1 sale of 4,000 ELVN shares at $20.25
Rhea-AI Filing Summary
Enliven Therapeutics insider sale by Chief Scientific Officer
Joseph P. Lyssikatos, Enliven Therapeutics' Chief Scientific Officer, reported a sale of 4,000 shares of the company's common stock on 09/26/2025 at a weighted average price of $20.2513 per share. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. After the reported disposition, the reporting person beneficially owns 927,688 shares indirectly through The Lyssikatos Revocable Trust dated 12/15/2011, for which he serves as trustee. The Form 4 was signed by power of attorney on 09/30/2025.
Positive
- Sale executed under a Rule 10b5-1 trading plan, indicating it was pre-planned (adopted 11/15/2024).
- Full post-transaction beneficial ownership disclosed: 927,688 shares held indirectly via The Lyssikatos Revocable Trust.
- Transaction details include weighted average price ($20.2513) and price range disclosure offer upon request.
Negative
- Disposition of 4,000 shares reduces the reporting person's direct/indirect holdings by that amount.
Insights
TL;DR: A routine, pre-planned insider sale of 4,000 shares under a 10b5-1 plan; holding remains substantial at 927,688 shares.
The reported transaction is a disposition executed under a Rule 10b5-1 trading plan, indicating the sale was pre-established and intended to avoid timing concerns associated with inside information. The sale size (4,000 shares) and the weighted average price ($20.2513) are disclosed; however, relative to the reported post-transaction beneficial ownership of 927,688 shares, the disposition appears modest. There is no other financial or operational information in the filing to suggest a change in company fundamentals.
TL;DR: Filing demonstrates standard disclosure and use of a 10b5-1 plan; signature by POA properly documented.
The Form 4 clearly identifies the reporting person, relationship to the issuer (Chief Scientific Officer), and the nature of indirect ownership via a revocable trust. The filing states the 10b5-1 plan adoption date (11/15/2024) and provides an undertaking to disclose trade-level prices on request. The signature executed by power of attorney on 09/30/2025 follows typical procedural practice for timely reporting. No governance issues or omissions are apparent from the document alone.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 4,000 | $20.2513 | $81K |
Footnotes (1)
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $20.015 to $20.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
